the metabolic syndrome including obesity, type 2 diabetes mellitus,
hypercholesterolemia and hypertension .Recently, there is accumulating
evidence that renin-angiotensin- system (RAS) appears likely to play an
important roles in various aspects of the metabolic syndrome.
The present study was designed to evaluate the potential
hepatoprotective effect of angiotensin converting enzyme inhibitor ACE!
(captopril) and angiotensin 11 type 1 receptor blocker ARB ( irbesartan) on
high fat diet (HFD) induced fatty liver in male rats. 40 male adult rats were
used; rats were separated randomly into 4 groups, ten rats in each group. 1st
group is control group was fed with standard chow diet and tap water. 2"
group received HFD (1% cholesterol and 10% coconut oil) via oral gavage
for 8wks with no medication. 3" group received HFD via oral gavage with
oral adminstration of captopri1100mg/kg/day for 8wks. 4thgroup received
HFD via oral gavage with oral adminstration of Irbesartan 30mg/kg/day for
8wks. The obtained data in the current work revealed that HFD feeding
resulted in significant increase (p<0.05) of serum alanine transaminase
(ALT), serum aspartate transaminase (AST) activity, serum total cholesterol
(TC), serum triglycerides (TG) and serum low density lipoprotein cholesterol
(LDL-c) with significant decrease (p<0.05) of serum high density lipoprotein
cholesterol (tDL-c), Albumin/globulin (A/G) ratio, prothrombin time (PT)
and serum reduced glutathione (GSH) compared with control group. Hepatic
damage was confirmed with histopathological studies. Both captopril and
irbesartan treatment decreased serum ALT. AST, TC, TG, LDL-c and
increased serum HDL-c, MG ratio and GSH significantly (p<0.05) compared
with 1-IFD group, also histopathology of the liver was improved. Captopril
affords better hepatoprotective effect as regard liver enzymes, total
cholesterol, triglycerides, LDL-c, A/G ratio and liver histopathology, while
there was insignificant difference in serum HDL-c and GSH between both
drugs.
Conclusively: Nonalcoholic fatty liver could be prevented by
coadminstration with either captopril or irbesartan suggesting new strategy in
prevention and treatement of NASH.
|
